Organization: Health Canada
Year: 2022
Month: September
Request Number: A-2022-000666
Request Summary: The four-year agreement between GlaxoSmithKline Canada and the Government of Canada, spanning through March 2026, which is for the supply of as many as 80 million doses of Arepanrix in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra, as announced in the press release found at: https://www.newswire.ca/news-releases/gsk-welcomes-agreement-with-the-government-of-canada-for-the-provision-of-pandemic-and-seasonal-influenza-vaccines-829453682.html.
Disposition: No records exist
Number of pages: 0